


- A7
CONT.
- Sub
H17
- 47. (New). A pharmaceutical composition comprising an anti-human antigen receptor according to claim 22 comprising at least one CDR and a pharmaceutically acceptable carrier--.
- 48. (New). A pharmaceutical composition comprising a receptor according to claim 43 wherein said CDR is CDR3--.
- 49. (New). A pharmaceutical composition comprising a receptor according to claim 44 wherein said CDR is CDR3--.
- 50. (New). The anti-human antigen receptor according to claim 45 wherein said CDR is CDR3--.
- 51. (New). The anti-human antigen receptor according to claim 46 wherein said CDR is CDR3--.
- 52. (New). The anti-human antigen receptor according to claim 47 wherein said CDR is CDR3--.

REMARKS

The foregoing amendments to claims are made to reflect the amended claims which were published in the International Application. The amendment does not affect the scope of the invention claimed and is supported by the originally filed claims and the specification. No new matter has been added, and entry is respectfully requested.

Respectfully submitted,

Dated: October 14, 1999


Maria C. H. Lin
Registration No. 29,323

MORGAN & FINNEGAN, L.L.P
345 Park Avenue
New York, New York 10154
(212) 758-4800
(212) 751-6849